Business Review · Miami Stem Cell + BetterStem

Section 1 · Executive Snapshot

Where we are. What's broken. What's the upside.

The audit trail (sources), the methodological rules, the KPI dashboard, and the three-and-three diagnostic — in that order. The reader sees the rigor before the numbers.

⊕ Data Foundation — What Powers This Business Review

5 platforms connected — all live — plus 4 MH·OS artifacts built for this engagement.

⊕ Connected Platforms · 5 Live

● Live

Meta Ads

L90D · 8 campaigns · $20,860 spend · 525 leads + 259 messenger conversations · $1.51 CPC · $40.76 CPM · 2.69% CTR. Powers Meta lead funnel + creative-velocity diagnostic.

● Live

Google Ads

L90D · 5 active campaigns · $13,556 spend · 70 conversions · $193.66 stated CPA · $11.84 CPC. Powers paid-search diagnostic + regulatory-scope audit (Joint Pain vs Hair Loss + Autoimmune).

● Live

Google Analytics 4

Jan → May 2026 · 2,134 sessions / 1,808 users L90D · 7 form starts. Powers traffic mix, engagement rate, 12-month timeline. Conversion-event configuration + UTM hygiene improvements scoped for Days 1-14.

● Live

Google Search Console

First 4 days flowing (May 7-10) · 226 impressions · 5 clicks · avg position 8.0. Powers organic-search query data + branded vs non-branded volume as the window expands.

● Live

GHL CRM

Backfill flowing · Apr 16 → May 6 · 8 contacts created across 7 active days. Stated 400-500 leads/mo doesn't yet reconcile with what GHL is recording — gap is one of the key diagnostics in Section 4.

⊕ MH·OS Artifacts · 4 Powering This Review

⊕ MH·OS Artifact

Brand Brain MH·OS

Brand identity, ICP personas (6), offers & pricing, product / service scope, objection-response framework (10). Powers ICP, pricing comparisons, voice guardrails.

⊕ MH·OS Artifact

Competitive Set MH·OS

12 profiles — Regenexx, QC Kinetix, Panama SCI, DVCSTEM, Beike, Duke, traditional ortho, US Stem Cell Inc. (FDA shutdown), South FL clinics, ABA conventional. Powers positioning map + acquisition-strategy table.

⊕ MH·OS Artifact

Meeting Transcripts MH·OS

Kickoff (2026-04-29, Greice Murphy + Remco Bos, 90 min). Powers stated lead volume (400-500/mo MSC), upsell rate (70-80%), revenue ($2-3.5M), founder positioning.

⊕ MH·OS Artifact

Business Priorities MH·OS

Internal priorities review (updated 2026-05-08). Powers opportunity sizing for L1 (CRM Reactivation), L2 (Google Ads), L3 (BetterStem Launch).

⊕ Analytical Standards — How We Source Every Number

Five rules govern how this Business Review verifies every claim. Every numeric claim is sourced and tagged.

Channel-measurement gap. Meta's "lead" action is a form-fill, not a treated patient. Stated CPA ≠ true CPA. Where the conversion event ≠ the business's true unit, we present both and N/A the right side until attribution is stitched.

Source confidence. H = directly verified from a connected platform or hard kickoff fact. M = derived from primary data with stated assumptions. L = single-source claim, treated as a working input until validated.

Derived metrics show the math. Effective cost-per-treated-patient, blended ticket, and any KPI built from a multiplier carry a derivation block with a sensitivity range and a path to upgrade confidence.

N/A is shown, not hidden. Google Ads, GHL leads, BetterStem performance, peer-reviewed clinical evidence — when missing, they appear as visible N/A markers with the unblock path. The visibility gap is part of the diagnosis.

Prior decision-makers are encoded signal. The current paid agency, the WordPress SEO partner, the GHL setup by Jana — their choices reflect context the BR doesn't have. Where this BR contradicts an incumbent decision, it's named — not overridden without measurement.

Source Legend: H Directly verified M Derived with stated assumptions L Single-source · validating

⊕ Central Diagnostic

The strategic frame for this engagement: BetterStem is where the category-defining upside sits — pediatric autism stem cell therapy under Right-to-Try is a structurally defensible US position no offshore competitor can replicate. MSC is the authority engine — 16 years, 8,500 procedures, founder-credibility — that makes BetterStem trustworthy to an audience that demands verification. The constraint isn't either business individually; it's the workstreams that activate BetterStem (founder-led content, parent community, authority-search ownership) which haven't been built — and which would compound back onto MSC's mature orthopedic engine if they had. Today's measurement layer is operational (5 platforms live), $34K of L90D paid spend is generating 595 leads + 259 conversations, and 54% of Google Ads spend ($7,294) is pointed at out-of-scope conditions (Hair Loss + Autoimmune) — that's the urgent action. The strategic action is BetterStem.

Combined Paid Spend (L90D)

$34,416 H

Meta $20.9K · Google $13.6K

~$11.5K / mo avg

Combined Leads (L90D)

595 H

+ 259 conversations

Meta 525 · Google 70

Out-of-Scope Spend (L90D)

$7,294 H

54% of Google Ads

Hair Loss + Autoimmune

Google Ads CPA (L90D)

$193.66 H

vs Meta stated $39.73

Joint Pain campaign: $221

Meta CPM (L90D)

$40.76 H

↑ vs benchmark

Med. cat. avg: $15–25

GHL Contacts (last 21 days)

8 H

~0.4 / day

Reconciles to stated 400-500/mo?

⚠ Top 3 Issues

BetterStem is dark on the category-defining opportunity. Zero campaigns, zero content, zero parent community, zero testimonials H. Meanwhile Panama compounds 20 years of parent-community trust; DVCSTEM scales medical-tourism funnels; Beike runs offshore SEO. → The most defensible US position in the category is being conceded to operators who can't actually replicate it

54% of Google Ads spend is out-of-scope. $7,294 / 90 days on Hair Loss + Autoimmune H — both outside FL SB 1768. Meta runs a Hair Loss creative on the same theme. → Active FTC + FDA enforcement risk; erodes the regulatory moat that defines both brands

Authority-search position on autism + Right-to-Try is uncontested but unbuilt. No US operator owns "stem cell autism United States" or "right to try autism" in organic or AI-answer engines L. Offshore competitors physically can't write the US-compliant content this audience demands. → A compounding moat is sitting on the table

↑ Top 3 Opportunities

Build BetterStem into a category, not a clinic. Founder-led content (Greice voice + RTT framework explainer), parent-community pilot, authority-search ownership. The growth engine is content + community, not paid funnel optimization. → Category-defining position; first revenue path in 60 days

Own the autism + RTT authority-search position. Long-form founder content on Right-to-Try, IRB framework, parent-objection responses. Compounds in AI-answer engines (ChatGPT, Perplexity, Claude, Gemini) where parents now start research. → Defensible because offshore competitors can't write US-compliant content; zero CAC at maturity

Transfer BetterStem workstreams back to MSC. Founder-voice content, parent-trust framework, authority SEO — same playbook applied to MSC's mature orthopedic engine. The activation engine works on both businesses. → MSC's 16-year track record + Greice's voice make the orthopedic side equally defensible

Section 2 · Current State Diagnosis

Funnel · Channel Mix · Creative Patterns

Three audit lenses. The funnel tells us where the engine breaks. The channel mix tells us where structural risk is concentrated. The creative section tells us why category-winning brands compound where MSC + BetterStem don't.

Funnel Performance & The Primary Growth Constraint

The funnel can't be fully diagnosed because the data layer isn't operational. The 5-stage patient funnel below combines what's verified from platform data (Meta sessions + leads, GA4 events) with what's stated in the kickoff (qualified leads, show rate, close rate, upsell). The constraint is one stage upstream of the funnel itself: measurement. Until events flow, every leak we name is a working hypothesis, not a finding.

L90D · MSC
combined channels

Sessions / Reach

2,134 GA4 sessions + 123K FB impressions 100%

↓ FB CTR 2.83% · GA4 engaged 38.5% H

Inquiries / Leads

~400-500 / mo (MSC stated) FB: 94 in 30d H

↓ ~20% qualification · "money + no cancer" gate M

Qualified

80-100 qualified leads / mo ~20%

↓ ~60% show · cat. benchmark 65-70% M

Consult Show

48-60 consultations ~12%

↓ ~60% close · 70-80% then add multi-joint upsell H

Treatment + Upsell

29-36 patients · $10-12K blended ticket ~7%

Sessions L90D H

2,134

~24 / day · Jan-May 2026

FB Leads L30D H

+120 messenger conv.

MSC Show Rate M

~60%

vs. 65-70% benchmark

Multi-Joint Upsell H

70-80%

drives blended ticket

⊕ Primary Growth Constraint

The constraint is measurement infrastructure, not funnel conversion.

Three breakages compound: (1) 0 GA4 conversion events recorded across 2,134 L90D sessions H — form-start events fire (7 events) but isn't flagged as conversion; (2) 53% "(direct)" + 29% "(referral)" means 82% of GA4 traffic is unattributable H — paid social isn't flowing UTMs; (3) GHL CRM daily metrics aren't flowing H — the lead system of record isn't piped. Net effect: $5,044 of Meta spend generated 94 leads + 120 conversations H, but neither GA4 nor the CRM can confirm what happened next. Stated CPL ($54) is real; Cost-Per-Treated-Patient is unmeasurable from primary data.

Strategic implication: Solving measurement is the highest-leverage single move in the engagement. Every other lever (CRM reactivation, Google Ads scale, BetterStem launch, show-rate optimization) sits downstream of attribution. Days 0-14: stitch the layer. Days 14+: every reallocation decision has confidence behind it.

Channel Mix — Imbalance & Dependency Risk

⊕ Structural Imbalance + Dependency Risk

$34K combined paid spend (L90D) split Meta-heavy (61%) / Google Ads (39%). $7.3K of Google spend is out-of-scope. Email is structurally absent. CRM reactivation is untouched.

Over-Concentrated · Regulatory Risk

Google Ads — Out-of-Scope Conditions

$7,294 (54% of Google spend) on Hair Loss + Auto Immune H — both outside FL SB 1768

Active FTC + FDA enforcement risk. Pause both campaigns immediately; redirect spend to Joint Pain + Brand Search (proven in-scope).

Under-Invested · Margin Lever

Email / SMS / Lifecycle

$0 spend · 0 active flows · 0 segmentation H · category-leading clinics see 20-30% revenue contribution

Stated 400-500 leads/mo enter, ~30 close, the rest are unowned. The lowest-CAC channel is structurally absent.

Latent · Compounding Asset

CRM Reactivation (3,500 GHL)

3,000-4,000 dormant contacts M · 1-3% reactivation × $10K = $10-30K/mo M

Every contact already qualified once. Highest-intent pool in the entire stack. ~$0 CAC. Untouched.

GA4 Session Mix · L90D H

2,134

Sessions

(direct) 53%

(referral) 29%

(organic) 13%

(not set) 5%

Stated CPL by Channel · target $50 H

$50 target

Meta Ads

$54 stated

$54

Google Ads

N/A — no campaigns

N/A

Organic / SEO

N/A — 13% sessions, 0 events

N/A

Referral / Yelp

N/A — untracked

N/A

Email / CRM

$0 (not active)

Channel	Spend (L90D)	Volume Signal	Stated CPA / CPL	Verdict
Meta Ads (paid social)	$20,860 H	525 leads + 259 conversations H	$39.73 / lead H	Performing
Google Ads — Joint Pain (in-scope)	$7,509 H	34 conversions / 90d	$220.86 / conv H	In Scope
Google Ads — Hair Loss (out-of-scope)	$5,044 H	46 conversions / 90d	$109.66 / conv H	Pause Immediately
Google Ads — Auto Immune (out-of-scope)	$2,250 H	10 conversions / 90d	$225.02 / conv H	Pause Immediately
Google Ads — Honolulu Search	$1,249 H	2 conversions / 90d	$624.57 / conv H	Paused; high CPA
Google Ads — Brand Search	$26 H	1 conversion / 90d	$25.50 / conv H	Cheapest channel
Organic / SEO	$0 direct L	274 organic sessions / 90d	N/A — 0 conversions tagged in GA4	Untracked
Direct / Branded	$0 direct	1,126 sessions / 90d (53%)	N/A — UTM hygiene gap inflates "direct"	Misattributed
Email / SMS / Lifecycle	$0 — not active H	0 flows · 0 segmentation	—	Absent
CRM Reactivation	$0 — dormant M	3,000-4,000 GHL contacts (stated)	~$0 CAC (latent)	Untapped

⊕ Derived Metric — True Cost Per Treated Patient

Combined paid spend across Meta + Google Ads through MSC's stated funnel. True cost-per-treated-patient is the business unit — and with both paid platforms now live, the math has real anchors.

Combined Spend (L90D)

$34,416 H

Meta $20.9K + Google $13.6K

Paid Leads × Funnel

595 × ~36% M

60% show × 60% close (kickoff-stated)

Cost / Treated Patient

~$161 M

vs. ~$10K blended ticket

Anchored: $34,416 spend, 595 leads (Meta 525 + Google 70) — direct from both ad platforms. Working assumption: paid lead quality matches MSC's stated 36% lead-to-treated rate — kickoff testimony; the GHL → treatment handoff isn't yet reconciled. Sensitivity: if paid leads convert at 50% of MSC org rate (18% effective), true cost = $321 / patient. At 150% (54%), true cost = $107. Resolution path: tag paid leads by source in GHL + reconcile to billing → 30 days cohorted → upgrades M → H. Either way, true CPA sits well below the ~$10K ticket.

Stated CPL / CPA by Channel H

Google — Brand

$26

$25.50

Meta Ads

$40

$39.73

Google — Hair Loss

$110 · out-of-scope

$109.66

Google — Joint Pain

$221

$220.86

Google — Auto Immune

$225 · out-of-scope

$225.02

Google — Honolulu

$625 · paused

$624.57

Cost / Treated Patient (derived) M

Google — Brand

~$71

Meta Ads

~$110

Google — Joint Pain

~$614

Out-of-scope channels

N/A — pause, don't optimize

N/A

Organic / Referral

N/A — UTM gap

N/A

⚠

How to read these charts: Stated CPL/CPA is what each platform reports (left). The right-hand chart applies MSC's stated funnel (60% show × 60% close) to estimate cost-per-treated-patient — derived, not measured. Out-of-scope channels (Hair Loss, Auto Immune) are intentionally N/A on the right: efficiency is the wrong question when the campaign shouldn't be running at all. Resolution path: tag paid leads by source in GHL → reconcile to billing → upgrade M → H within 30 days.

⊕ 12-Month Primary KPI Timeline — Sessions / mo + Meta Spend

The shape over time matters more than any single point estimate. Sessions are visible from Jan 2026 forward; Meta spend appeared April 2026. The analytics layer is younger than the marketing engine — most pre-2026 history is N/A.

N/A

361

479

898

648

235*

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

May 26

What unblocks the gaps: GA4 history pre-Jan 2026 either wasn't tracked or hasn't been ingested into the analytics layer. Sessions peaked at 898 in March 2026, dropped 28% in April (when Meta spend launched at $3,816 — counter-intuitive). May 2026 (235*) is partial-month through May 8. Resolution path: backfill GA4 history (if available), confirm whether March peak was campaign-driven or organic, attribute the April drop. Hypothesis (not finding): Meta paid traffic landing on pages that aren't tagged for GA4 — would explain spend up + attributed sessions down.

Creative Patterns — What's Winning vs. What's Running

⊕ Category Creative Patterns vs. Current Creative

Cash-pay regenerative medicine is a high-trust, high-objection category. Category-winning brands lead with founder credibility, peer-validated outcomes, and patient-story video. Current creative is one campaign deep — virtual consultation, single format.

↑ What's Winning in the Category

Hook

Founder-direct ("16 years, 8,500 procedures, what we won't promise") · patient-pain-specific opener · before/after-day-1

Format

UGC patient testimonials · founder selfie-style explainers · objection-response shorts (FAQ → answer in 30s)

Source

First-party patient stories · founder voice · clinical staff intros · facility tours

Authority

Specific numbers (procedures, years), regulatory framework named, transparent about limitations

⚠ What's Running Today

Hook

Generic "Virtual Consult — Florida State" — no founder voice, no patient story, no specificity

Format

3 campaigns over 31d H · format breakdown not yet pulled · no UGC pipeline · no testimonial collection

Source

Agency-produced — likely stock or staff photography. Greice's voice (the moat) is absent.

Authority

Generic offer-driven · no procedure count, no Right-to-Try framework named, no founder credentials

The category-winning pattern is credibility, not promotion. MSC's founder + 16-year track record + Right-to-Try moat are exactly what this category rewards — but they aren't appearing in the creative library that runs the engine. Greice's own description of her voice ("compliance-first, comfortable naming the gray area") is the most defensible asset in stem cell marketing today, given FTC enforcement on hype-prone competitors.

Active campaigns L30D H

cat. benchmark: 15-30/mo

CTR (link clicks) H

2.83%

healthy for medical

CPM H

$40.86

~2x category benchmark

Patient testimonials collected

0 H

despite "patients in office every other day"

Right-to-Try mentions in creative

0 L

moat not in market

Creative Distribution — What's Working / Broken / Missing

↑ Working

Virtual Consult — Florida State drives ~74% of FB spend with 2.83% CTR H. The offer (free virtual consultation) lowers commitment friction. The geo-targeting (FL state) is correct given SB 1768's jurisdictional limits.

⚠ Broken

Hair Loss campaign ($1,008 spend) sits outside FL SB 1768's authorized scope (orthopedic, pain, wound care) H. Regulatory review required immediately. Plus: 3 campaigns in 31d is category-bottom velocity.

+ Missing

Founder voice, patient testimonials, BetterStem campaigns, Right-to-Try framework messaging. The structural moat isn't in market. Zero BetterStem campaigns running on Meta or Google H.

Section 3 · The Right-to-Try Moat

Why this is category positioning, not messaging.

Right-to-Try isn't a marketing angle for BetterStem. It's the legal architecture that makes US-based pediatric autism stem cell therapy possible — and the structural moat against every offshore competitor. Treating it as messaging is a competitive misfire. Treating it as architecture is the moat.

The Three-Pillar Framework

Three independent regulatory anchors, combined. No US clinic offering autism stem cell therapy runs all three. Most offshore operators run none of them.

Pillar 1

IRB-Approved Protocol

Independent ethics-board review of the treatment protocol, informed-consent language, adverse-event monitoring, and outcome tracking. IRB approval is the foundation of credible clinical research in the US.

Enables: defensible clinical posture; protects against FTC deceptive-practice claims; documents that the protocol is not improvised.

Pillar 2

FDA-Regulated Products

Cells sourced exclusively from FDA-registered, AATB-certified, cGMP-compliant US labs. Minimally manipulated. Same regulatory product class being used in Duke University's Phase II IMPACT trial.

Enables: regulatory differentiation from offshore + non-compliant US operators (US Stem Cell Inc., SCIA); enforcement risk decreases as competitors get shut down.

Pillar 3

Right-to-Try Pathway

Federal Right to Try Act (21 USC 360bbb-0a). Allows patients to access investigational therapies that have completed Phase I FDA safety testing and are in active clinical trials. Treatment under the same product class as Duke IMPACT (NCT04089579).

Enables: US-domestic legal pathway no offshore operator can replicate; defensible category position.

⊕

Combined, these three create a defensible US position that Panama / Cayman / China cannot replicate. Offshore operators exist because they operate outside US jurisdiction. They cannot adopt this framework without losing the regulatory arbitrage that makes them economically viable. The three pillars don't just protect BetterStem — they describe the moat.

US-Domestic vs. Offshore — Geographic Positioning

X-axis: Travel friction for an autistic child + family (low ↔ high). Y-axis: Regulatory recourse if anything goes wrong (foreign jurisdiction ↔ US legal system). BetterStem occupies the only uncontested quadrant.

Foreign Jurisdiction

US Legal Recourse

High Travel Friction

Low Travel Friction

BetterStem · Miami

Duke (trial · waitlisted)

Panama Stem Cell

Mexico clinics

DVCSTEM · Cayman

Beike · Bangkok

Conventional ABA

The uncontested quadrant. BetterStem is the only operator with US legal recourse + low travel friction + investigational stem cell therapy for pediatric autism. Duke shares the quadrant but is enrollment-bottlenecked (waitlisted, 50% placebo arm). Every offshore operator requires international travel with an autistic child — Greice's most-cited parent objection. Conventional ABA shares the quadrant but doesn't address the underlying biology. This is category-defining real estate. Today, it's empty.

The Trust Signal Hierarchy

Autism parents don't move on performance creative. They move on a stack of verified signals. The strongest signals at the top of this stack — founder credibility + regulatory framework + clinical track record — are the assets BetterStem already has but doesn't yet lead with.

Founder credibility — Greice Murphy

EY Entrepreneur of the Year 2021. Founded Advanced Care Partners (healthcare staffing), scaled to 1,300+ employees, Inc. 5000 seven consecutive years. Not someone who started a clinic last year. Built a 1,300-person healthcare company before this.

Three-pillar legal framework

IRB + FDA-regulated cells + Right-to-Try Act. The architecture, not the messaging. When parents (or their analytical spouse) verify the IRB, look up the RTT Act, and call the FDA, the answer holds.

Miami Stem Cell — 16 years, 8,500 procedures

The clinical infrastructure behind BetterStem isn't speculative — it's a high-volume, 16-year regenerative practice with 92% reported improvement on its mature orthopedic side. MSC is the proof that the clinical operation behind BetterStem works at scale. This is the strategic role of MSC: authority + operational credibility for the BetterStem opportunity.

Same product class as Duke IMPACT trial

Cells sourced from FDA-registered labs, same regulatory class as the cells used in Duke's $15M NIH/Marcus-Foundation-backed Phase II trial (NCT04089579). Investigational, not experimental.

Transparent limitations

"Not everybody benefits." "Results are not guaranteed." "65-70% experience meaningful improvement." Honest about adverse-event rates (2% mild, 20% temporary behavioral). Verifiability earns trust where performance creative loses it.

Parent peer testimony (forthcoming)

The final tier — and the one BetterStem doesn't yet have. Panama has 20 years of parent-community testimony; BetterStem has zero. The first 20-30 founding families become the institutional asset.

Compliance Posture as Moat — The Enforcement Pattern

FDA and FTC enforcement in the regenerative medicine category is tightening. Each enforcement action strengthens the position of compliant operators. The pattern is visible in the public record.

⊕ Enforcement 1

US Stem Cell Inc. — FDA shutdown

Sunrise, FL (same federal district as Miami Stem Cell). Shut down by FDA for unregistered cell processing; one patient went blind from autologous adipose-derived treatment. The boundary case for what the three-pillar framework prevents.

⊕ Enforcement 2

SCIA — FTC settlement, Jan 2025

Stem Cell Institute of America: $5.15M FTC settlement for deceptive marketing practices. Co-founders banned from making stem cell health claims. The pattern is widening, not narrowing.

⊕ Implication

The moat compounds with enforcement

Each enforcement action against non-compliant operators (US clinics + offshore as US patients increasingly demand verification) makes BetterStem's compliant position more defensible. Compliance is the moat — and the moat compounds with time.

⊕ Strategic Position

Right-to-Try is not a tagline. It's the category position.

Treating Right-to-Try as a marketing angle is the competitive misfire. The framework is what makes BetterStem possible inside the United States — it is the architecture, not the copy. The strategic posture for BetterStem is to own the Right-to-Try category — through content, founder voice, parent community, and authority-search position. Performance marketing optimizes a funnel; category positioning makes the funnel inevitable.

And the same posture applies to MSC. The 16-year track record + Greice's voice + FL SB 1768 framework give MSC the same authority position in regenerative orthopedic that Right-to-Try gives BetterStem in pediatric autism. The workstreams transfer directly.

Section 4 · The Autism Parent Journey

Why this category is bought, not sold.

Autism parents don't respond to performance marketing. They respond to verification. The decision is research-led, peer-validated, and trust-gated — and runs on a 6-to-18-month cycle. Marketing into this audience requires understanding the psychology, not optimizing the funnel.

The Two Decision-Maker Archetypes

Built from kickoff transcripts + parent-community research. Both archetypes are research-heavy, slow-cycle, peer-validated. Neither is moved by performance marketing.

Maria — The Exhausted Researcher

Profile

38, married, two-income household. Daughter (6, moderate support needs) diagnosed at 3. Three years of 5-day-a-week ABA, speech, OT.

State

Exhausted but not desperate. Has seen incremental progress with ABA — tired of incremental. Knows the Duke trial exists but can't get a spot. Considered Panama; the international flight with her daughter stopped her.

Behavior

Three years in autism parent FB groups. Reads every clinical paper she can find. First-reaction quote on finding BetterStem: "I didn't know that's legal in the United States."

What closes her

Physician consultation that answers without overselling. Greice's personal involvement. RTT framework explained in plain language. Conversation with another BetterStem parent.

David & Keisha — The Skeptical Advocates

Profile

42/40, engineer + part-time work. Son (8, high support needs) diagnosed at 2. 30 hrs/wk ABA + speech + OT. Split decision authority.

State

Analytical determined / protective skeptical. David treats the decision like an engineering problem; wants p-values. Keisha has watched friends spend money on therapies that didn't work — the skepticism check.

Behavior

David has a spreadsheet comparing every stem cell provider. Has read the RTT Act. Will look up the IRB number and may call the FDA. Keisha asks about adverse-event percentages, emergency protocols, and how many autistic children specifically have been treated.

What closes them

Complete transparency. Specific clinical-trial citations. The cell-count protocol vs. the Duke protocol. Verifiable IRB documentation. Any evasion ends the conversation.

Both archetypes share a fundamental pattern: they bring evidence to the table and demand evidence back. They are not converted by hooks. They are converted by verification. The marketing that works for this audience is the marketing that hands them more rigorous information than they came with.

The 6-to-18-Month Decision Journey

Autism parents move through six observable stages between first awareness of stem cell therapy and treatment commitment. The bottleneck is not awareness or top-of-funnel. The bottleneck is trust-building (stages 4-5).

Stage 1

Diagnosis + ABA

Years 1-3 post-diagnosis

Conventional therapy. Plateau begins to show. First Googling "is there anything else?"

Stage 2

Research Mode

Months 1-12 after looking beyond ABA

Google searches, FB groups, clinical-paper reading. Learns Panama exists. Knows Duke is trial-only.

Stage 3

Skepticism + Deepening

Months 6-18

Compares offshore vs. domestic. Weighs travel logistics. Finds parent reviews. Verifies the legal frameworks.

Stage 4

Community Validation

Ongoing across 6-18 months

Talks to parents who've done it. Reads outcome cohorts. Bottleneck for BetterStem: no community yet exists.

Stage 5

Consultation

First clinic contact

Asks objection-loaded questions: "Is this legal?" "What's the cell count?" "Can I talk to another parent?" Closes on physician transparency.

Stage 6

Treatment Commitment

After trust built

Usually after parent-peer conversation + physician trust + verified framework.

Decision Cycle6-18 months from first awareness to treatment. Performance marketing optimizes weeks; this audience operates on quarters.

Funnel BottleneckTrust-building (Stage 4) + objection-handling (Stage 5). Where most parents who research stem cells decide not to proceed.

Conversion RateEstimated ~5% of parents who reach Stage 2 reach Stage 6 across the category. BetterStem's job is to widen the cohort through Stages 4-5.

What Closes the Conversation vs. What Ends It

Built from kickoff testimony + autism-parent community research. Closes-vs-bounces is a sharper diagnostic than CPL: the audience converts on different signals than performance marketing optimizes for.

↑ Closes

Founder-voice content. Greice on camera, plain language, naming the gray area.

RTT framework explained as architecture. Not a marketing claim — the legal pathway.

Specific outcome data. "65-70% experience meaningful improvement." "2% mild adverse events." Numbers, not adjectives.

Transparent limitations. "Not everybody benefits." "Results are not guaranteed."

Parent-peer conversation. A 20-minute call with another BetterStem family closes more cases than any creative.

Verifiable credentials. IRB documentation, FDA registration of supplier labs, physician credentials.

↓ Bounces

Performance hooks. "Transform your child's life." "Imagine the possibilities."

Cure language. Guarantees, before/after promises, miraculous-result claims.

Generic testimonials. Stock parent photos, unverifiable quotes, no specific outcomes.

Evasion on adverse events. "Generally safe." "Most patients tolerate well." Vagueness reads as red flag.

Sales pressure. Limited-time offers, urgency triggers, hard-close tactics.

Hidden details. Pre-payment before consultation, unclear what's included, financing buried.

⊕

Strategic implication: The audience that BetterStem (and MSC's most defensible patient) actually serves rewards founder voice, framework transparency, and peer validation. Performance creative isn't just less effective — for this audience, it's negative-signal. The growth engine should be content + community, not paid-funnel optimization first.

Where Trust Is Built — The Community Layer

Parents validate the decision in community before — and during — the formal funnel. Panama's 20-year head-start in this layer is its real competitive advantage. BetterStem's white space is the same lane, designed properly.

⊕ Where parents are today

Autism FB groups + Reddit r/Autism_Parenting

Existing high-traffic forums where stem-cell-curious parents seek and share experiences. Panama parents dominate the conversation by tenure. BetterStem has zero presence; the existing posts about US-based options are speculative or out-of-date.

BetterStem move: structured participation, not lurking — founder Q&A threads, IRB explainer drops, parent-cohort recruitment.

⊕ Where trust scales

Private BetterStem parent cohort

50-100 founding families. Monthly virtual support. Standardized 6/12/24-month autism progression tracking (CARS, ADOS, parent-rated). Generates first-party outcome data + testimonials simultaneously.

Defensibility: first 20-30 families become the institutional asset. The cohort itself becomes a trust-signal no offshore competitor can replicate.

⊕ Where authority compounds

AI-answer engines + organic search

Parents now start research in ChatGPT, Perplexity, Claude, Gemini. Currently no US operator owns "stem cell autism United States" or "right to try autism" in those answers. Long-form founder content compounds in both organic and AI-answer surfaces.

BetterStem move: own the explainer layer. Section 8 details this as a featured opportunity.

⊕ Where credibility transfers

Regional developmental pediatricians

Parents seek their child's pediatrician's opinion. Currently most pediatricians don't know about RTT or US-domestic stem cell options. Partnership network with 10-15 developmental pediatricians = pre-consultation referral path that decouples BetterStem from Miami-only friction.

Defensibility: network effects; first 5 partnerships are hard, next 5 are easier.

Section 5 · Category Dynamics

How the regenerative medicine market actually behaves

Demand patterns + sub-segment growth + the structural shift that opened FL's market. The Right-to-Try moat and parent-journey dynamics specific to BetterStem are detailed in Sections 3 and 4; this section frames the broader market both businesses operate in.

⊕ Seasonality — Annual Demand Index

Stem cell consultations follow a dual-peak pattern: January ("New Year, new joints") and Q2-Q3 (active/outdoor → injury → consultation). Q4 is dead — patients defer to year-end HSA + post-holiday financial recovery.

11%

10%

11%

10%

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

Pattern logic: Joint pain spikes with activity (Q2-Q3) and resolutions (Jan). Surgery scheduling for fall pulls Sep up. December "year-end HSA spend" produces a small bump but is offset by holiday deferrals. Implication: Q1 + Q2 are the prime acquisition windows. L — pattern is industry-typical, not measured directly from MSC traffic; resolution path is to overlay GA4 sessions across 12+ months once UTM hygiene flows.

⊕ Faster-Growth Sub-Segment

Pediatric Autism Stem Cell

~30-40% YoY L · category-level estimate from Beike + Panama public claims L

Driven by: Duke IMPACT trial validation, Right-to-Try Act precedent expansion (Montana 2023, others pending), parent communities compounding on Facebook + Reddit. BetterStem's window: 36 months before larger US competitors enter.

⊕ Steady-Growth Sub-Segment

Regenerative Orthopedic

~12-15% YoY L · industry analyst estimates L

Driven by: aging population, surgery aversion, FL SB 1768 unlocking advertising, FTC enforcement clearing weak competitors. MSC's 16-year head-start + 8,500 procedures + $50M expansion is structural advantage — but Regenexx (100+ locations) + QC Kinetix (100+ franchises) compound geographic reach faster.

⊕

Structural Shift — FL SB 1768 (effective July 1, 2025). State law authorizes physicians to administer stem cell therapy for orthopedic, pain, and wound care. Florida is now one of the most permissive US jurisdictions for cash-pay regenerative medicine H. MSC's window is open — and the state-level framework is the regulatory complement to BetterStem's federal Right-to-Try framework (Section 3). Same authority posture, two jurisdictional pathways.

⊕ Annual Demand-Trigger Timeline (DTC patient lens)

Jan

"New Year, new joints"

Resolution-driven search peaks. Highest organic intent. Acquisition window 1.

Apr–Jun

Activity → Injury → Consult

Outdoor season starts. Knee/hip/back pain becomes acute. Cortisone alternatives sought. Acquisition window 2.

Jul–Aug

Plateau

Travel + summer pulls attention. Lead volume softens 15-20%.

Sep

Surgery alt-search

Patients evaluating fall surgery scheduling search for alternatives. Acquisition window 3.

Oct–Dec

HSA + holiday

Dec HSA-spend uptick offset by holiday financial deferrals. Lowest acquisition efficiency.

Section 6 · Core Problems

5 problems, sorted by strategic impact

Each problem is a Cause → Impact statement, anchored in primary data. Severity badges: red = critical, amber = high, sky = medium. Problem 1 is urgent; Problems 2 and 3 are where the category-defining opportunity is being conceded.

Problem 1 · Critical

54% of Google Ads spend is out-of-scope

⚠ CRITICAL

$7,294 of $13,556 Google Ads spend in L90D points at Hair Loss + Autoimmune H — both outside FL SB 1768. Meta runs a Hair Loss creative on the same theme. The most efficient campaign on Google Ads ($110 CPA) is the one that needs to be paused.

Cause

Agency-managed paid stack without cross-functional regulatory review. Greice's compliance discipline is high; the vendor stack isn't aligned. Efficiency was optimized without compliance.

Impact

Active FTC + FDA enforcement risk that erodes the regulatory moat both brands depend on. US Stem Cell Inc. (same federal district) was shut down for less.

Problem 2 · High

BetterStem is dark on the category-defining opportunity

HIGH

Zero Meta campaigns. Zero Google Ads campaigns. Zero email. Zero parent-community presence. Zero testimonials. ~10 patients in pipeline lifetime H. The only US operator with the full three-pillar Right-to-Try framework isn't yet in market.

Cause

Operational lift not yet built — Voice AI on RingCentral, GHL funnels (Jana's workstream), financing partner. And no content engine: founder voice, parent-community pilot, authority-search position all sit at zero.

Impact

Category-defining position being conceded. Panama compounds 20 years of parent trust every month BetterStem stays dark. Duke remains enrollment-bottlenecked. First-mover advantage on US-domestic Right-to-Try is a clock.

Problem 3 · High

Authority-search position on autism + RTT is uncontested but unbuilt

HIGH

No US operator owns "stem cell autism United States" or "right to try autism" in organic search or AI-answer engines (ChatGPT, Perplexity, Claude, Gemini) L. Offshore competitors physically cannot write the US-compliant content this audience demands — their copy exposes their non-compliance.

Cause

No founder-authored long-form content. WordPress agency producing generic SEO posts that don't address Right-to-Try, IRB, or parent-objection responses. AI-answer engines are answering parent questions with offshore + research-paper context.

Impact

A compounding moat is sitting on the table. Authority content ranks for years. AI-answer engines cite verified sources. Both reward US-compliant operators and penalize the alternative — but only if the content exists.

Problem 4 · High

Paid-to-CRM handoff doesn't reconcile

HIGH

GHL CRM sync is live but recording only 8 contacts across 21 days H. Meta reports 525 leads in L90D; Google Ads adds 70 conversions. Plus the Meta funnel itself has shifted (347 lead forms/mo Nov → 19/mo May; messenger 4 → 115). Strategy ambiguity until the handoff is verified.

Cause

Likely two combined factors: paid leads land in Meta Lead Forms or direct calls that don't write back to GHL; agency pivoted Meta creative from lead-form to messenger-CTA around March without documentation.

Impact

Lead-to-treatment attribution is incomplete for the mature MSC business — and impossible to set up correctly for BetterStem before it launches.

Problem 5 · Medium

3,000-4,000 dormant GHL contacts

MEDIUM

3,000-4,000 contacts in GHL that already passed qualification M (kickoff-stated; not yet reconciled in the live GHL feed) — zero reactivation campaigns, zero segmentation, zero email infrastructure on top.

Cause

No internal lifecycle ops. Marketing has been entirely top-of-funnel.

Impact

Highest-intent pool in the stack is idle. Near-zero CAC reactivation foregone. Same lifecycle playbook applies to BetterStem patients once the cohort exists.

Section 7 · Competitive Landscape

Where MSC + BetterStem sit in the cash-pay regenerative market

Two competitive sets, one positioning system. The combined client sits at a structural advantage on regulatory + founder credibility — and behind on geographic reach + parent-community penetration.

Positioning Map — Regulatory Risk × Patient Accessibility

X-axis: regulatory framework (US-compliant ↔ offshore/unregulated). Y-axis: patient accessibility (mass-market ↔ premium-niche). The combined client sits in the upper-middle: compliant + accessible. Offshore competitors and US enforcement targets cluster opposite corners.

Mass-Market

Premium-Niche

Offshore / Unregulated

US-Compliant Framework

Panama SCI

Mexico clinics

DVCSTEM (Cayman)

Beike Biotech

QC Kinetix

Traditional ortho

Regenexx

Duke (trial)

US Stem Cell Inc. (shut down)

MSC + BetterStem

Strategic position: The combined client occupies the uncontested middle — compliant US framework with accessible-but-not-discount pricing. Offshore competitors (Panama, DVCSTEM, Beike) cannot match domestic legal recourse. Franchise discounters (QC Kinetix) cannot match founder-credibility + 16-yr operational depth. The structural advantage is real; the execution gap is geographic reach + content density.

Creative & Messaging Patterns

How each competitor positions and what hooks land. Client row highlighted.

Brand	Positioning	Messaging Style	Channel Strength	Where they win	Where we win
Regenexx Orthopedic · 100+ MD network	"Surgery alternative for serious athletes." Premium-clinical.	Peer-reviewed evidence-led; physician-credentialed. Outcome registries cited.	Physician licensing + national geo coverage	Published clinical research; geographic reach (100+ vs 2)	Cell quality (allogeneic UC-MSC vs. patient-derived BMC); upsell mastery
QC Kinetix Orthopedic · 100+ franchises	"46,000+ lives transformed." Mass-market accessibility.	Volume social proof; direct-response.	Franchise + call-center + local TV	Price ($5K-$8K entry); national scale	Cell quality; physician-led care vs. NPs; FTC-compliance discipline
Panama Stem Cell Institute Pediatric autism + adult · Panama	"20 years, 80,000+ procedures, Golden Cells." Offshore authority.	Parent-FB-community storytelling; founder Riordan publishes.	Organic + 20yr parent word-of-mouth	Volume (80,000+ procedures) + parent community + Riordan publications	Domestic (no passport, 1-day treatment); Right-to-Try US legal recourse; FTC-compliant copy
DVCSTEM Cayman Islands	"300M culture-expanded UC-MSCs, IRB-approved, Cayman regulation."	Higher-cell-count claim; international medical tourism positioning.	Medical tourism aggregators	Higher cell count (regulatory advantage of culture expansion)	Domestic + cheaper all-in (~$10K-$16K vs. $22K-$30K total); IV-only less invasive
Duke University (IMPACT) Academic clinical trial	"FDA-authorized Phase II, NIH/Marcus Foundation-backed."	Academic gravitas; evidence-led.	Institutional + research community	Free + Duke credibility	Guaranteed treatment (no placebo arm); domestic backup when Duke says no
Miami Stem Cell + BetterStem Orthopedic + autism · FL/HI	16-year practice + Right-to-Try. Compliance-first founder.	Greice's voice is the moat — but absent from current creative.	Meta Ads (3 campaigns) · GHL CRM · WP SEO (8 posts/wk)	—	Right-to-Try moat; EY-recognized founder; only US clinic with full 3-pillar legal framework for autism

Acquisition Strategy — How Each Brand Generates Demand

Brand	Primary Lever	Creative Velocity	Geo Coverage	Lifecycle Leverage	SEO Authority
Regenexx	Physician licensing	Medium	100+ US locations	Patient-registry-driven	High (peer-review citations)
QC Kinetix	Franchise + call center	High (TV + paid social)	100+ franchises	Standardized	Medium
Panama SCI	Parent community + organic	Low (slow + steady)	1 (Panama City)	Word-of-mouth	Medium-High (20yr)
DVCSTEM	Medical tourism aggregators	Medium	1 (Cayman)	Limited	Medium
Duke (IMPACT)	Academic + clinical trial registry	N/A	1 (Durham, NC)	N/A	Very High (academic)
MSC + BetterStem	Meta Ads + Google Ads + WP SEO	Low (3 campaigns / 31d)	2 (Miami + Honolulu)	None active	Low (no topical authority)

Compliance Posture & Authority Differentiation

Two columns the messaging table doesn't capture: how each competitor's regulatory framework holds up under scrutiny, and where each derives its authority. These are the trust dimensions parents and the FTC both evaluate.

Brand	Regulatory Framework	Compliance Risk Posture	Source of Authority
Regenexx	US physician network · in-practice exemption	Low · outcome-registry-backed	Peer-reviewed publications + 100+ physician credentialing
QC Kinetix	Franchise + practitioner-driven	Medium · NPs delivering care, FTC-pattern proximity	"46,000+ lives transformed" volume + local market presence
Panama SCI	Panama jurisdiction · no US oversight	Medium · operates outside FDA/FTC; 2019 paper retracted	20-year tenure · 80,000+ procedures · Riordan publications
DVCSTEM	Cayman jurisdiction · culture-expanded cells	Medium · Cayman regulation is robust but foreign	Cell-count claim (300M) + IRB-approved + 2-day protocol
Beike Biotech	China/Thailand · multi-protocol invasive treatments	High · 6-8 spinal injections, foreign legal recourse	"World's largest MSC provider" scale claim
Duke Univ. (IMPACT)	FDA-authorized Phase II trial	Very Low · academic IRB + FDA oversight	NIH + Marcus Foundation backing · top-10 medical school
US Stem Cell Inc.	Was: autologous in-house · no oversight	Shut down by FDA	N/A — boundary case
SCIA	Was: deceptive marketing pattern	$5.15M FTC settlement (Jan 2025)	N/A — boundary case
MSC + BetterStem	FL SB 1768 (state) + Federal Right-to-Try + IRB + FDA-regulated cells	Lowest in commercial competitive set	Greice Murphy: EY Entrepreneur 2021 · 1,300-employee healthcare scale · 16-year MSC clinical record · the three-pillar framework

⊕

The compliance posture is the moat. Each FTC enforcement action against a non-compliant operator (SCIA, US Stem Cell) widens the gap between MSC + BetterStem and the rest of the field. Offshore competitors cannot adopt the three-pillar US framework without losing the regulatory arbitrage that makes them viable. The position compounds with time and enforcement.

Where MSC + BetterStem Sits Today

⊕ Strategic Position

Structural advantage on regulatory + founder + cell-quality. Execution gap on geographic reach, creative velocity, and lifecycle/community.

The combined moat — Greice's EY-recognized operational track record + 16 years + 8,500 procedures + 70-80% upsell discipline + the only US clinic running the full 3-pillar Right-to-Try framework for pediatric autism — is genuinely defensible. It is also genuinely absent from the current creative library. Regenexx out-publishes on clinical evidence; QC Kinetix out-scales on geo; Panama out-communities on parent referrals. MSC + BetterStem's job over 90 days is not to replicate any of those — it's to put the actual moat into market.

The execution gap is closeable in 90 days. Founder-direct creative + patient testimonial collection + Right-to-Try framework messaging + parent-community pilot are all 30-60 day plays. Geographic franchise replication is the 36-month play (BetterStem's stated 5-10 location target).

White Space Opportunities — Uncontested Lanes

Six lanes where no competitor has presence and the combined client has structural fit.

⊕ White Space 1

AI-Answer Engine Authority — "Right-to-Try Autism"

ChatGPT, Perplexity, Claude, and Gemini are increasingly the first stop for parent research. Currently no US operator owns the answer to "stem cell autism United States" or "right to try autism" in these surfaces. Founder-authored content that explains the three-pillar framework correctly becomes the citable source. Offshore operators physically cannot author US-compliant content.

Defensibility: AI answer engines reward verified, US-compliant sources and penalize hype-prone alternatives. Authority compounds with citations.

⊕ White Space 2

Right-to-Try Parent Cohort + Outcome Tracking

Structured BetterStem family community with monthly virtual support + standardized 6/12/24-mo autism progression assessments. Generates first-party outcome data + testimonials simultaneously. Panama has informal FB groups; Duke prohibits inter-family contact (blinding); BetterStem can own this lane outright.

Defensibility: First 20-30 founding families = institutional asset. Outcomes data can become BetterStem's first peer-reviewable evidence base.

⊕ White Space 3

Compliant US Autism Content Authority

Founder-authored long-form on Right-to-Try, IRB framework, FDA-regulated cell sourcing, parent-objection responses. Built once, ranks for years on the exact ICP search terms. Offshore competitors can't write this (would expose their non-compliance); Duke has academic content but not parent-language explainers.

Defensibility: Topical SEO authority on the most defensible terms. Compounding asset, zero CAC at maturity.

⊕ White Space 4

Telemedicine Pre-Enrollment via Regional Pediatricians

Partner with 10+ developmental pediatricians (Seattle, Dallas, Chicago, Boston, Denver) for virtual Right-to-Try eligibility screening. Decouples BetterStem from Miami-only friction. Panama can't replicate (no US pediatrician network); Duke is enrollment-bottlenecked.

Defensibility: Network effect. Each regional partnership compounds — first 5 are hard, next 5 are easier.

⊕ White Space 5

Founder-Voice as Cross-Brand Authority Asset

Greice's EY-recognized voice + the same compliance-first framing applies to both BetterStem (autism) and MSC (orthopedic). The same long-form content engine activates both brands. No competitor pairs a single recognizable founder with a dual-brand regulatory framework.

Defensibility: The founder is the asset. Workstreams built for BetterStem (content, community, authority SEO) transfer directly to MSC's mature orthopedic engine.

⊕ White Space 6

Employer / Self-Insured Bundle Pilots (3-5yr)

Pilot contracts with self-insured employer plans (500-2,000 employees) covering MSC orthopedic + BetterStem autism as covered benefits. Generates de-identified outcome data + creates "covered benefit" precedent. No competitor in either category has attempted this.

Defensibility: 3-5 year play. Establishes "autism stem cell as covered benefit" category-first.

Section 8 · Growth Opportunities

5 strategic directions, sized against measurable lift

Opportunity 1 is urgent (compliance). Opportunities 2 + 3 are where the category-defining upside sits. Opportunities 4 + 5 compound the workstreams across both brands. Strategic POV first; tactical sequencing is the work product of Section 10 and the Day-14 plan presentation.

Opportunity 1 · Critical · Compliance

Reclaim the regulatory moat

URGENT

Out-of-scope paid campaigns ($7,294 of L90D Google Ads spend on Hair Loss + Autoimmune; Meta's Hair Loss creative) plus WordPress condition listings exceeding SB 1768 actively erode the compliance moat that defines both brands. The strategic posture is to redirect spend into proven in-scope demand (Joint Pain + Brand Search) and tighten the vendor stack against the same review standard the founder applies.

Strategic Direction

Compliance becomes a cross-functional review standard, not a periodic audit. The moat compounds with each FTC enforcement action against non-compliant operators — but only if MSC + BetterStem stay on the correct side of it.

Expected Impact

Eliminates active regulatory risk · redirects ~$2.5K/mo to in-scope conversion · preserves category position

Sequencing

First week of the engagement · single highest-priority move

Opportunity 2 · Category-Defining

Build BetterStem into a category, not a clinic

STRATEGIC

BetterStem's structural moat — Right-to-Try + IRB + FDA-regulated cells + EY-recognized founder — is uncontested in the US. The audience that buys this category (autism parents) rewards founder voice, community validation, and verified frameworks; it does not respond to performance creative. The strategic posture is to compound the moat into a category position through content, community, and authority — not to optimize a paid funnel.

Strategic Direction

Founder-led content engine · private parent cohort with structured outcome tracking · regional pediatrician partnerships · paid funnel tests that learn the audience, not optimize a CPL.

Expected Impact

Category-defining US position · path to $62-125K/mo at maturity (5-10 patients × $12.5K) L · first BetterStem revenue within ~60 days

Sequencing

Days 30-90 · gated on RingCentral + GHL completion · first revenue Day 60

Opportunity 3 · Compounding

Own the AEO + SEO authority position on autism + Right-to-Try

COMPOUNDING

This category is research-led: parents spend 6-18 months searching before treatment. Their first stop is increasingly AI-answer engines (ChatGPT, Perplexity, Claude, Gemini) — and no US operator currently owns those answers for "stem cell autism United States" or "right to try autism." Offshore competitors physically cannot author the US-compliant content that earns citations in those surfaces. The strategic posture is to become the canonical source.

Strategic Direction

Founder-authored long-form on Right-to-Try, IRB framework, FDA-regulated sourcing, parent-objection responses · structured data + citable outcomes · optimized for both organic search and AI-answer-engine retrieval.

Expected Impact

Compounding moat — ranks for years, zero CAC at maturity · feeds Stages 2-4 of the parent journey (Section 4) · defensible because offshore competitors cannot adopt US-compliant framing without losing their regulatory arbitrage

Sequencing

Days 14-90 · early-mover advantage decreases monthly as larger US operators consider entering

Opportunity 4 · Quick (MSC)

CRM Reactivation across 3,500 dormant contacts

QUICK

MSC's mature engine has 3,000-4,000 contacts that already passed qualification M. Every contact is higher-intent than any new paid lead; near-zero CAC. The strategic posture is to convert the existing qualified pool before scaling paid acquisition.

Strategic Direction

Segmented lifecycle activation — by procedure type, time-since-last-treatment, upsell eligibility. The same lifecycle architecture serves the BetterStem cohort once it exists.

Expected Impact

+$10-30K/mo within 30 days M · 1-3 reactivated patients/mo · ~$0 CAC

Sequencing

Days 7-21 · first revenue Day 14-30

Opportunity 5 · Cross-Brand

Transfer BetterStem workstreams to MSC

TRANSFER

The activation engine built for BetterStem (founder-voice content, parent-trust framework, authority-search position, peer-validation cohort) applies directly to MSC's mature orthopedic side. MSC patients are also research-led — they're a Yelp-comparing, surgery-averse audience that rewards founder credibility + 16-year track record over performance creative. The strategic posture is to treat MSC as the second application of the same playbook, not a separate engineering problem.

Strategic Direction

Greice founder content series adapted to orthopedic objections · MSC patient testimonial program (16-year backlog, untapped) · authority content on SB 1768 + regenerative orthopedic evidence base · show-rate and close-rate playbook lifted from BetterStem's parent-trust framework.

Expected Impact

+$30-50K/mo on MSC M · show rate 60% → 70%; close rate 60% → 68% · 3-5 incremental patients/mo · compounds with BetterStem authority work

Sequencing

Days 14-90 · activation in lockstep with Opportunity 2; same workstream, two destinations

Section 10 · Strategic Arc

Stabilize → Scale → Compound

Sequencing logic — not a tactical to-do list. Stabilize before scale; scale before expand. Each phase compounds the last.

Days 0-30 · Stabilize

Reclaim the moat. Make the engine measurable.

The opening 30 days are about preserving the foundation: regulatory posture, measurement integrity, and the latent reactivation pool. Stabilize before scale; scale before expand.

1. Reclaim the regulatory moat

Out-of-scope paid campaigns pause; spend redirects to in-scope demand; the WordPress site is reviewed against the same standard the founder applies. Compliance becomes a cross-functional posture, not a periodic audit.

2. Close the measurement layer

All 5 platforms live; the remaining gaps (UTMs, conversion events, paid-to-CRM attribution) close on the same schedule. Cost-per-treated-patient becomes a defensible number, not a derived estimate.

3. Activate the dormant CRM

3,000-4,000 already-qualified contacts segmented and re-engaged with the lifecycle architecture that will later serve the BetterStem cohort. First reactivated patient is the proof point.

Days 30-60 · Scale

Activate BetterStem. Transfer to MSC.

The middle phase moves from MSC operational fixes to the category-defining BetterStem opportunity. The same workstream activates both brands. This phase is about optionality.

4. Build BetterStem's content engine

Founder-voice long-form on Right-to-Try, IRB, parent-objection responses. Optimized for organic + AI-answer engines. The authority position compounds in surfaces where parents now start research.

5. First paid funnel learns the audience

A measured Meta + Google test on autism-parent ICP — designed to learn what closes vs. what bounces (Section 4), not to optimize a CPL. First BetterStem revenue path opens.

6. MSC takes the same workstream

Founder-voice content adapted to orthopedic objections. Patient-testimonial program activated. Same authority asset, different brand. The activation engine works on both.

Days 60-90 · Compound

Build the durable assets that don't decay.

The final phase invests in assets that compound: parent community, authority content, regional partnerships. The goal is channels that work without ongoing campaign spend.

7. Founding parent cohort

A private BetterStem family community with structured outcome tracking becomes the institutional asset Panama has and Duke prohibits. The first 20-30 families are the moat.

8. Lifecycle architecture across both brands

Welcome, pre-consult, post-treatment, referral. The lifecycle layer that's structurally absent today, deployed once, serving both engines.

9. Geographic decoupling

Regional developmental-pediatrician partnerships decouple BetterStem from Miami-only friction. Authority content compounds in search + AI-answer surfaces. The position becomes harder to displace each month.

Metric	Healthy	Trigger	Action	Owner
Meta CPM	<$30	>$45	Refresh creative; rotate hooks	Growth
Stated CPL (Meta)	<$60	>$90	Pause + diagnose; check audience saturation	Growth
Cost / treated patient (derived)	<$200	>$350	Reallocate spend; investigate FB lead quality	Growth
GA4 key events / mo	>50	<20	Audit tag manager + GA4 config; check conversion fires	Eng
GHL contacts / mo (lead volume)	>450	<350	Source diagnostic; check landing page CVR	Sales
Consult show rate	>65%	<55%	Reminder sequence audit; pre-consult video	Ops
Close rate (after consult)	>55%	<45%	Sales review; objection-response training	Ops

Miami Stem Cell + BetterStemBusiness Review

Funnel Performance & The Primary Growth Constraint

Channel Mix — Imbalance & Dependency Risk

Creative Patterns — What's Winning vs. What's Running

The Three-Pillar Framework

US-Domestic vs. Offshore — Geographic Positioning

The Trust Signal Hierarchy

Compliance Posture as Moat — The Enforcement Pattern

The Two Decision-Maker Archetypes

The 6-to-18-Month Decision Journey

What Closes the Conversation vs. What Ends It

Where Trust Is Built — The Community Layer

Positioning Map — Regulatory Risk × Patient Accessibility

Creative & Messaging Patterns

Acquisition Strategy — How Each Brand Generates Demand

Compliance Posture & Authority Differentiation

Where MSC + BetterStem Sits Today

White Space Opportunities — Uncontested Lanes

Miami Stem Cell + BetterStem
Business Review